Abstract
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and has become prevalent in the adult population worldwide, given the ongoing obesity pandemic. NAFLD comprises several hepatic disorders, ranging from fatty liver to nonalcoholic steatohepatitis (NASH), cirrhosis, and carcinoma. Excessive fat accumulation in the liver can induce the development of fatty liver, whereas the progression of fatty liver to NASH involves various complex factors. The crucial difference between fatty liver and NASH is the presence of inflammation and fibrosis, the emergence of which is closely associated with the action of immune cells and immunological factors, such as chemokines and cytokines. Thus, expanding our understanding of immunological mechanisms contributing to NASH pathogenesis will lead to the identification of therapeutic targets and the development of viable therapeutics against NASH.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alkhouri N, Dixon LJ, Feldstein AE (2009) Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol 3:445–451. https://doi.org/10.1586/egh.09.32
Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TA, Yerian L, Zein NN, Feldstein AE (2012) Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 32:297–302. https://doi.org/10.1111/j.1478-3231.2011.02639.x
Almeda-Valdes P, Aguilar Olivos NE, Barranco-Fragoso B, Uribe M, Méndez-Sánchez N (2015) The role of dendritic cells in fibrosis progression in nonalcoholic fatty liver disease. Biomed Res Int 2015:768071. https://doi.org/10.1155/2015/768071
Antonucci L, Porcu C, Timperi E, Santini SJ, Iannucci G, Balsano C (2020) Circulating neutrophils of nonalcoholic steatohepatitis patients show an activated phenotype and suppress T lymphocytes activity. J Immunol Res 2020:4570219. https://doi.org/10.1155/2020/4570219
Asfaha S, Dubeykovskiy AN, Tomita H, Yang X, Stokes S, Shibata W, Friedman RA, Ariyama H, Dubeykovskaya ZA, Muthupalani S, Ericksen R, Frucht H, Fox JG, Wang TC (2013) Mice that express human interleukin-8 have increased mobilization of immature myeloid cells, which exacerbates inflammation and accelerates colon carcinogenesis. Gastroenterology 144:155–166. https://doi.org/10.1053/j.gastro.2012.09.057
Bae EA, Seo H, Kim IK, Jeon I, Kang CY (2019) Roles of NKT cells in cancer immunotherapy. Arch Pharm Res 42:543–548. https://doi.org/10.1007/s12272-019-01139-8
Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N, Huss S, Klussmann S, Eulberg D, Luedde T, Trautwein C, Tacke F (2012) Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61:416–426. https://doi.org/10.1136/gutjnl-2011-300304
Berres ML, Koenen RR, Rueland A, Zaldivar MM, Heinrichs D, Sahin H, Schmitz P, Streetz KL, Berg T, Gassler N, Weiskirchen R, Proudfoot A, Weber C, Trautwein C, Wasmuth HE (2010) Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest 120:4129–4140. https://doi.org/10.1172/jci41732
Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A, Gugenheim J, Barr J, Mato JM, Le Marchand-Brustel Y, Tran A, Gual P (2010) Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS ONE 5:e13577. https://doi.org/10.1371/journal.pone.0013577
Bhattacharjee J, Kirby M, Softic S, Miles L, Salazar-Gonzalez RM, Shivakumar P, Kohli R (2017) Hepatic natural killer T-cell and CD8 + T-cell signatures in mice with nonalcoholic steatohepatitis. Hepatol Commun 1:299–310. https://doi.org/10.1002/hep4.1041
Braunersreuther V, Viviani GL, Mach F, Montecucco F (2012) Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 18:727–735. https://doi.org/10.3748/wjg.v18.i8.727
Breuer DA, Pacheco MC, Washington MK, Montgomery SA, Hasty AH, Kennedy AJ (2020) CD8(+) T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 318:G211-g224. https://doi.org/10.1152/ajpgi.00040.2019
Brownell J, Polyak SJ (2013) Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin Cancer Res 19:1347–1352. https://doi.org/10.1158/1078-0432.Ccr-12-0928
Cao S, Liu M, Sehrawat TS, Shah VH (2021) Regulation and functional roles of chemokines in liver diseases. Nat Rev Gastroenterol Hepatol 18:630–647. https://doi.org/10.1038/s41575-021-00444-2
Capucetti A, Albano F, Bonecchi R (2020) Multiple roles for chemokines in neutrophil biology. Front Immunol 11:1259. https://doi.org/10.3389/fimmu.2020.01259
Chang SH (2019) T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer. Arch Pharm Res 42:549–559. https://doi.org/10.1007/s12272-019-01146-9
Chatzigeorgiou A, Chung KJ, Garcia-Martin R, Alexaki VI, Klotzsche-Von Ameln A, Phieler J, Sprott D, Kanczkowski W, Tzanavari T, Bdeir M, Bergmann S, Cartellieri M, Bachmann M, Nikolakopoulou P, Androutsellis-Theotokis A, Siegert G, Bornstein SR, Muders MH, Boon L, Karalis KP, Lutgens E, Chavakis T (2014) Dual role of B7 costimulation in obesity-related nonalcoholic steatohepatitis and metabolic dysregulation. Hepatology 60:1196–210. https://doi.org/10.1002/hep.27233
Chen GY, Nuñez G (2010) Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10:826–837. https://doi.org/10.1038/nri2873
Chen J, Montagner A, Tan NS, Wahli W (2018a) Insights into the role of PPARβ/δ in NAFLD. Int J Mol Sci. https://doi.org/10.3390/ijms19071893
Chen W, Zhang J, Fan HN, Zhu JS (2018b) Function and therapeutic advances of chemokine and its receptor in nonalcoholic fatty liver disease. Ther Adv Gastroenterol 11:1756284818815184. https://doi.org/10.1177/1756284818815184
Chen J, Liang B, Bian D, Luo Y, Yang J, Li Z, Zhuang Z, Zang S, Shi J (2019) Knockout of neutrophil elastase protects against western diet induced nonalcoholic steatohepatitis in mice by regulating hepatic ceramides metabolism. Biochem Biophys Res Commun 518:691–697. https://doi.org/10.1016/j.bbrc.2019.08.111
Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G (2011) Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 54:133–144. https://doi.org/10.1002/hep.24341
Delli Bovi AP, Marciano F, Mandato C, Siano MA, Savoia M, Vajro P (2021) Oxidative stress in non-alcoholic fatty liver disease. An updated mini review. Front Med (Lausanne) 8:595371. https://doi.org/10.3389/fmed.2021.595371
Diaz Soto MP, Lim JK (2020) Evaluating the therapeutic potential of cenicriviroc in the treatment of nonalcoholic steatohepatitis with fibrosis: a brief report on emerging data. Hepat Med 12:115–123. https://doi.org/10.2147/hmer.S230613
Diedrich T, Kummer S, Galante A, Drolz A, Schlicker V, Lohse AW, Kluwe J, Eberhard JM, Schulze Zur Wiesch J (2020) Characterization of the immune cell landscape of patients with NAFLD. PLoS ONE 15:e0230307. https://doi.org/10.1371/journal.pone.0230307
Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE (2013) Kupffer cells in the liver. Compr Physiol 3:785–797. https://doi.org/10.1002/cphy.c120026
Du Plessis J, Korf H, Van Pelt J, Windmolders P, Vander Elst I, Verrijken A, Hubens G, Van Gaal L, Cassiman D, Nevens F, Francque S, Van Der Merwe S (2016) Pro-inflammatory cytokines but not endotoxin-related parameters associate with disease severity in patients with NAFLD. PLoS ONE 11:e0166048. https://doi.org/10.1371/journal.pone.0166048
Fan Y, Zhang W, Wei H, Sun R, Tian Z, Chen Y (2020) Hepatic NK cells attenuate fibrosis progression of non-alcoholic steatohepatitis in dependent of CXCL10-mediated recruitment. Liver Int 40:598–608. https://doi.org/10.1111/liv.14307
Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M (2021) Non-alcoholic steatohepatitis (NASH)—a review of a crowded clinical landscape, driven by a complex disease. Drug Des Devel Ther 15:3997–4009. https://doi.org/10.2147/dddt.S315724
Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF (2021) A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med 385:1547–1558. https://doi.org/10.1056/NEJMoa2036205
Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ (2018a) Mechanisms of NAFLD development and therapeutic strategies. Nat Med 24:908–922. https://doi.org/10.1038/s41591-018-0104-9
Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, Francque S, Farrell G, Kowdley KV, Craxi A, Simon K, Fischer L, Melchor-Khan L, Vest J, Wiens BL, Vig P, Seyedkazemi S, Goodman Z, Wong VW, Loomba R, Tacke F, Sanyal A, Lefebvre E (2018b) A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 67:1754–1767. https://doi.org/10.1002/hep.29477
Gadd VL, Skoien R, Powell EE, Fagan KJ, Winterford C, Horsfall L, Irvine K, Clouston AD (2014) The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology 59:1393–1405. https://doi.org/10.1002/hep.26937
Gao B, Tsukamoto H (2016) Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe? Gastroenterology 150:1704–1709. https://doi.org/10.1053/j.gastro.2016.01.025
García-López MA, Sánchez-Madrid F, Rodríguez-Frade JM, Mellado M, Acevedo A, García MI, Albar JP, Martínez C, Marazuela M (2001) CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells. Lab Invest 81:409–418. https://doi.org/10.1038/labinvest.3780248
Garcia-Martinez I, Santoro N, Chen Y, Hoque R, Ouyang X, Caprio S, Shlomchik MJ, Coffman RL, Candia A, Mehal WZ (2016) Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9. J Clin Invest 126:859–864. https://doi.org/10.1172/jci83885
Ghazarian M, Revelo XS, Nøhr MK, Luck H, Zeng K, Lei H, Tsai S, Schroer SA, Park YJ, Chng MHY, Shen L, D’angelo JA, Horton P, Chapman WC, Brockmeier D, Woo M, Engleman EG, Adeyi O, Hirano N, Jin T, Gehring AJ, Winer S, Winer DA (2017) Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome. Sci Immunol. https://doi.org/10.1126/sciimmunol.aai7616
Giles DA, Moreno-Fernandez ME, Stankiewicz TE, Cappelletti M, Huppert SS, Iwakura Y, Dong C, Shanmukhappa SK, Divanovic S (2016) Regulation of inflammation by IL-17A and IL-17F modulates non-alcoholic fatty liver disease pathogenesis. PLoS ONE 11:e0149783. https://doi.org/10.1371/journal.pone.0149783
Gomes AL, Teijeiro A, Burén S, Tummala KS, Yilmaz M, Waisman A, Theurillat JP, Perna C, Djouder N (2016) Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell 30:161–175. https://doi.org/10.1016/j.ccell.2016.05.020
Gomez Perdiguero E, Klapproth K, Schulz C, Busch K, Azzoni E, Crozet L, Garner H, Trouillet C, De Bruijn MF, Geissmann F, Rodewald HR (2015) Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 518:547–551. https://doi.org/10.1038/nature13989
Gomez-Santos L, Luka Z, Wagner C, Fernandez-Alvarez S, Lu SC, Mato JM, Martinez-Chantar ML, Beraza N (2012) Inhibition of natural killer cells protects the liver against acute injury in the absence of glycine N-methyltransferase. Hepatology 56:747–759. https://doi.org/10.1002/hep.25694
Goto T, Itoh M, Suganami T, Kanai S, Shirakawa I, Sakai T, Asakawa M, Yoneyama T, Kai T, Ogawa Y (2018) Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis. Sci Rep 8:8157. https://doi.org/10.1038/s41598-018-26383-8
Groom JR, Luster AD (2011) CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 89:207–215. https://doi.org/10.1038/icb.2010.158
Guo J, Friedman SL (2010) Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair 3:21. https://doi.org/10.1186/1755-1536-3-21
Han MS, Lim YM, Quan W, Kim JR, Chung KW, Kang M, Kim S, Park SY, Han JS, Park SY, Cheon HG, Dal Rhee S, Park TS, Lee MS (2011) Lysophosphatidylcholine as an effector of fatty acid-induced insulin resistance. J Lipid Res 52:1234–1246. https://doi.org/10.1194/jlr.M014787
Harley IT, Stankiewicz TE, Giles DA, Softic S, Flick LM, Cappelletti M, Sheridan R, Xanthakos SA, Steinbrecher KA, Sartor RB, Kohli R, Karp CL, Divanovic S (2014) IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology 59:1830–1839. https://doi.org/10.1002/hep.26746
Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, Shiffman ML, Camargo M, Li G, Kersey K, Jia C, Zhu Y, Djedjos CS, Subramanian GM, Myers RP, Gunn N, Sheikh A, Anstee QM, Romero-Gomez M, Trauner M, Goodman Z, Lawitz EJ, Younossi Z (2020) Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol 73:26–39. https://doi.org/10.1016/j.jhep.2020.02.027
Hartl D, Krauss-Etschmann S, Koller B, Hordijk PL, Kuijpers TW, Hoffmann F, Hector A, Eber E, Marcos V, Bittmann I, Eickelberg O, Griese M, Roos D (2008) Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases. J Immunol 181:8053–8067. https://doi.org/10.4049/jimmunol.181.11.8053
Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjøro K, Aukrust P (2006) Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 44:1167–1174. https://doi.org/10.1016/j.jhep.2006.02.011
He Y, Hwang S, Cai Y, Kim SJ, Xu M, Yang D, Guillot A, Feng D, Seo W, Hou X, Gao B (2019) MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes. Hepatology 70:1150–1167. https://doi.org/10.1002/hep.30645
He Y, Rodrigues RM, Wang X, Seo W, Ma J, Hwang S, Fu Y, Trojnár E, Mátyás C, Zhao S, Ren R, Feng D, Pacher P, Kunos G, Gao B (2021) Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis. J Clin Invest. https://doi.org/10.1172/jci141513
Heier EC, Meier A, Julich-Haertel H, Djudjaj S, Rau M, Tschernig T, Geier A, Boor P, Lammert F, Lukacs-Kornek V (2017) Murine CD103(+) dendritic cells protect against steatosis progression towards steatohepatitis. J Hepatol 66:1241–1250. https://doi.org/10.1016/j.jhep.2017.01.008
Heinrichs D, Berres ML, Nellen A, Fischer P, Scholten D, Trautwein C, Wasmuth HE, Sahin H (2013) The chemokine CCL3 promotes experimental liver fibrosis in mice. PLoS ONE 8:e66106. https://doi.org/10.1371/journal.pone.0066106
Henning JR, Graffeo CS, Rehman A, Fallon NC, Zambirinis CP, Ochi A, Barilla R, Jamal M, Deutsch M, Greco S, Ego-Osuala M, Bin-Saeed U, Rao RS, Badar S, Quesada JP, Acehan D, Miller G (2013) Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology 58:589–602. https://doi.org/10.1002/hep.26267
Her Z, Tan JHL, Lim YS, Tan SY, Chan XY, Tan WWS, Liu M, Yong KSM, Lai F, Ceccarello E, Zheng Z, Fan Y, Chang KTE, Sun L, Chang SC, Chin CL, Lee GH, Dan YY, Chan YS, Lim SG, Chan JKY, Chandy KG, Chen Q (2020) CD4(+) T cells mediate the development of liver fibrosis in high fat diet-induced NAFLD in humanized mice. Front Immunol 11:580968. https://doi.org/10.3389/fimmu.2020.580968
Hirotani T, Yamamoto M, Kumagai Y, Uematsu S, Kawase I, Takeuchi O, Akira S (2005) Regulation of lipopolysaccharide-inducible genes by MyD88 and Toll/IL-1 domain containing adaptor inducing IFN-beta. Biochem Biophys Res Commun 328:383–392. https://doi.org/10.1016/j.bbrc.2004.12.184
Hou X, Yin S, Ren R, Liu S, Yong L, Liu Y, Li Y, Zheng MH, Kunos G, Gao B, Wang H (2021) Myeloid-cell-specific IL-6 signaling promotes microRNA-223-enriched exosome production to attenuate NAFLD-associated fibrosis. Hepatology 74:116–132. https://doi.org/10.1002/hep.31658
Hughes CE, Nibbs RJB (2018) A guide to chemokines and their receptors. Febs J 285:2944–2971. https://doi.org/10.1111/febs.14466
Hwang S, Yang YM (2021) Exosomal microRNAs as diagnostic and therapeutic biomarkers in non-malignant liver diseases. Arch Pharm Res 44:574–587. https://doi.org/10.1007/s12272-021-01338-2
Hwang S, He Y, Xiang X, Seo W, Kim SJ, Ma J, Ren T, Park SH, Zhou Z, Feng D, Kunos G, Gao B (2020a) Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets. Hepatology 72:412–429. https://doi.org/10.1002/hep.31031
Hwang S, Wang X, Rodrigues RM, Ma J, He Y, Seo W, Park SH, Kim SJ, Feng D, Gao B (2020b) Protective and detrimental roles of p38α mitogen-activated protein kinase in different stages of nonalcoholic fatty liver disease. Hepatology 72:873–891. https://doi.org/10.1002/hep.31390
Hwang S, Yun H, Moon S, Cho YE, Gao B (2021) Role of neutrophils in the pathogenesis of nonalcoholic steatohepatitis. Front Endocrinol (Lausanne) 12:751802. https://doi.org/10.3389/fendo.2021.751802
Ibrahim SH, Hirsova P, Tomita K, Bronk SF, Werneburg NW, Harrison SA, Goodfellow VS, Malhi H, Gores GJ (2016) Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes. Hepatology 63:731–744. https://doi.org/10.1002/hep.28252
Jaeschke H (2011) Reactive oxygen and mechanisms of inflammatory liver injury: present concepts. J Gastroenterol Hepatol 26(Suppl 1):173–179. https://doi.org/10.1111/j.1440-1746.2010.06592.x
Kado A, Tsutsumi T, Enooku K, Fujinaga H, Ikeuchi K, Okushin K, Moriya K, Yotsuyanagi H, Koike K (2019) Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells. J Gastroenterol 54:730–741. https://doi.org/10.1007/s00535-019-01565-x
Kahraman A, Schlattjan M, Kocabayoglu P, Yildiz-Meziletoglu S, Schlensak M, Fingas CD, Wedemeyer I, Marquitan G, Gieseler RK, Baba HA, Gerken G, Canbay A (2010) Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. Hepatology 51:92–102. https://doi.org/10.1002/hep.23253
Kim N, Lee HH, Lee HJ, Choi WS, Lee J, Kim HS (2019) Natural killer cells as a promising therapeutic target for cancer immunotherapy. Arch Pharm Res 42:591–606. https://doi.org/10.1007/s12272-019-01143-y
Koop AC, Thiele ND, Steins D, Michaëlsson E, Wehmeyer M, Scheja L, Steglich B, Huber S, Schulze Zur Wiesch J, Lohse AW, Heeren J, Kluwe J (2020) Therapeutic targeting of myeloperoxidase attenuates NASH in mice. Hepatol Commun 4:1441–1458. https://doi.org/10.1002/hep4.1566
Krenkel O, Tacke F (2017) Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol 17:306–321. https://doi.org/10.1038/nri.2017.11
Krijgsman D, Hokland M, Kuppen PJK (2018) The role of natural killer T cells in cancer—a phenotypical and functional approach. Front Immunol 9:367. https://doi.org/10.3389/fimmu.2018.00367
Lee J, Park JS, Roh YS (2019) Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease. Arch Pharm Res 42:935–946. https://doi.org/10.1007/s12272-019-01178-1
Li Z, Soloski MJ, Diehl AM (2005) Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 42:880–885. https://doi.org/10.1002/hep.20826
Li H, Zhou Y, Wang H, Zhang M, Qiu P, Zhang M, Zhang R, Zhao Q, Liu J (2020) Crosstalk between liver macrophages and surrounding cells in nonalcoholic steatohepatitis. Front Immunol 11:1169. https://doi.org/10.3389/fimmu.2020.01169
Liu CC, Ko HJ, Liu WS, Hung CL, Hu KC, Yu LY, Shih SC (2019) Neutrophil-to-lymphocyte ratio as a predictive marker of metabolic syndrome. Medicine (Baltimore) 98:e17537. https://doi.org/10.1097/md.0000000000017537
Liu K, Wang FS, Xu R (2021) Neutrophils in liver diseases: pathogenesis and therapeutic targets. Cell Mol Immunol 18:38–44. https://doi.org/10.1038/s41423-020-00560-0
Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, Mchutchison JG, Goodman ZD, Afdhal NH, Charlton MR (2018) The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology 67:549–559. https://doi.org/10.1002/hep.29514
Luedde T, Schwabe RF (2011) NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 8:108–118. https://doi.org/10.1038/nrgastro.2010.213
Ma X, Hua J, Mohamood AR, Hamad AR, Ravi R, Li Z (2007) A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology 46:1519–1529. https://doi.org/10.1002/hep.21823
Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Stroncek DF, Terabe M, Kapoor V, Elgindi M, Han M, Thornton AM, Zhang H, Egger M, Luo J, Felsher DW, Mcvicar DW, Weber A, Heikenwalder M, Greten TF (2016) NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature 531:253–257. https://doi.org/10.1038/nature16969
Malhi H, Gores GJ (2008) Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 28:360–369. https://doi.org/10.1055/s-0028-1091980
Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11:519–531. https://doi.org/10.1038/nri3024
Maricic I, Marrero I, Eguchi A, Nakamura R, Johnson CD, Dasgupta S, Hernandez CD, Nguyen PS, Swafford AD, Knight R, Feldstein AE, Loomba R, Kumar V (2018) Differential activation of hepatic invariant NKT cell subsets plays a key role in progression of nonalcoholic steatohepatitis. J Immunol 201:3017–3035. https://doi.org/10.4049/jimmunol.1800614
Marra F, Tacke F (2014) Roles for chemokines in liver disease. Gastroenterology 147:577–594. https://doi.org/10.1053/j.gastro.2014.06.043
Martin-Murphy BV, You Q, Wang H, De La Houssaye BA, Reilly TP, Friedman JE, Ju C (2014) Mice lacking natural killer T cells are more susceptible to metabolic alterations following high fat diet feeding. PLoS ONE 9:e80949. https://doi.org/10.1371/journal.pone.0080949
Meizlish ML, Franklin RA, Zhou X, Medzhitov R (2021) Tissue homeostasis and inflammation. Annu Rev Immunol 39:557–581. https://doi.org/10.1146/annurev-immunol-061020-053734
Mendez-Sanchez N, Cruz-Ramon VC, Ramirez-Perez OL, Hwang JP, Barranco-Fragoso B, Cordova-Gallardo J (2018) New aspects of lipotoxicity in nonalcoholic steatohepatitis. Int J Mol Sci. https://doi.org/10.3390/ijms19072034
Mihm S (2018) Danger-associated molecular patterns (DAMPs): molecular triggers for sterile inflammation in the liver. Int J Mol Sci. https://doi.org/10.3390/ijms19103104
Miura K, Yang L, Van Rooijen N, Ohnishi H, Seki E (2012) Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol 302:G1310–G1321. https://doi.org/10.1152/ajpgi.00365.2011
Miyagi T, Takehara T, Uemura A, Nishio K, Shimizu S, Kodama T, Hikita H, Li W, Sasakawa A, Tatsumi T, Ohkawa K, Kanto T, Hiramatsu N, Hayashi N (2010) Absence of invariant natural killer T cells deteriorates liver inflammation and fibrosis in mice fed high-fat diet. J Gastroenterol 45:1247–1254. https://doi.org/10.1007/s00535-010-0272-y
Morigny P, Houssier M, Mouisel E, Langin D (2016) Adipocyte lipolysis and insulin resistance. Biochimie 125:259–266. https://doi.org/10.1016/j.biochi.2015.10.024
Mukai K, Miyagi T, Nishio K, Yokoyama Y, Yoshioka T, Saito Y, Tanaka S, Shigekawa M, Nawa T, Hikita H, Sakamori R, Yoshihara H, Imai Y, Hiramatsu N, Tatsumi T, Takehara T (2016) S100A8 production in CXCR2-expressing CD11b + Gr-1high cells aggravates hepatitis in mice fed a high-fat and high-cholesterol diet. J Immunol 196:395–406. https://doi.org/10.4049/jimmunol.1402709
Nguyen GT, Green ER, Mecsas J (2017) Neutrophils to the ROScue: mechanisms of NADPH oxidase activation and bacterial resistance. Front Cell Infect Microbiol 7:373. https://doi.org/10.3389/fcimb.2017.00373
Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, Goforth MH, Subramanian V, Mukundan L, Ferrante AW, Chawla A (2008) Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab 7:496–507. https://doi.org/10.1016/j.cmet.2008.04.003
Ogier JM, Nayagam BA, Lockhart PJ (2020) ASK1 inhibition: a therapeutic strategy with multi-system benefits. J Mol Med (Berl) 98:335–348. https://doi.org/10.1007/s00109-020-01878-y
Olson TS, Ley K (2002) Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 283:R7–28. https://doi.org/10.1152/ajpregu.00738.2001
Onal G, Kutlu O, Gozuacik D, Dokmeci Emre S (2017) Lipid droplets in health and disease. Lipids Health Dis 16:128. https://doi.org/10.1186/s12944-017-0521-7
Ou R, Liu J, Lv M, Wang J, Wang J, Zhu L, Zhao L, Xu Y (2017) Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice. Endocrine 57:72–82. https://doi.org/10.1007/s12020-017-1323-4
Panzitt K, Wagner M (2021) FXR in liver physiology: multiple faces to regulate liver metabolism. Biochim Biophys Acta Mol Basis Dis 1867:166133. https://doi.org/10.1016/j.bbadis.2021.166133
Parthasarathy G, Revelo X, Malhi H (2020) Pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatol Commun 4:478–492. https://doi.org/10.1002/hep4.1479
Patouraux S, Rousseau D, Bonnafous S, Lebeaupin C, Luci C, Canivet CM, Schneck AS, Bertola A, Saint-Paul MC, Iannelli A, Gugenheim J, Anty R, Tran A, Bailly-Maitre B, Gual P (2017) CD44 is a key player in non-alcoholic steatohepatitis. J Hepatol 67:328–338. https://doi.org/10.1016/j.jhep.2017.03.003
Pawlak M, Lefebvre P, Staels B (2015) Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol 62:720–733. https://doi.org/10.1016/j.jhep.2014.10.039
Pérez-Martínez L, Pérez-Matute P, Aguilera-Lizarraga J, Rubio-Mediavilla S, Narro J, Recio E, Ochoa-Callejero L, Oteo JA, Blanco JR (2014) Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). J Antimicrob Chemother 69:1903–1910. https://doi.org/10.1093/jac/dku071
Pulli B, Ali M, Iwamoto Y, Zeller MW, Schob S, Linnoila JJ, Chen JW (2015) Myeloperoxidase-hepatocyte-stellate cell cross talk promotes hepatocyte injury and fibrosis in experimental nonalcoholic steatohepatitis. Antioxid Redox Signal 23:1255–1269. https://doi.org/10.1089/ars.2014.6108
Rada P, González-Rodríguez Ã, García-Monzón C, Valverde ÃM (2020) Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis 11:802. https://doi.org/10.1038/s41419-020-03003-w
Rai RP, Liu Y, Iyer SS, Liu S, Gupta B, Desai C, Kumar P, Smith T, Singhi AD, Nusrat A, Parkos CA, Monga SP, Czaja MJ, Anania FA, Raeman R (2020) Blocking integrin α(4)β(7)-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis. J Hepatol 73:1013–1022. https://doi.org/10.1016/j.jhep.2020.05.047
Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A (2016) Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150:1147-1159e5. https://doi.org/10.1053/j.gastro.2016.01.038
Rau M, Schilling AK, Meertens J, Hering I, Weiss J, Jurowich C, Kudlich T, Hermanns HM, Bantel H, Beyersdorf N, Geier A (2016) Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver. J Immunol 196:97–105. https://doi.org/10.4049/jimmunol.1501175
Régnier M, Polizzi A, Lippi Y, Fouché E, Michel G, Lukowicz C, Smati S, Marrot A, Lasserre F, Naylies C, Batut A, Viars F, Bertrand-Michel J, Postic C, Loiseau N, Wahli W, Guillou H, Montagner A (2018) Insights into the role of hepatocyte PPARα activity in response to fasting. Mol Cell Endocrinol 471:75–88. https://doi.org/10.1016/j.mce.2017.07.035
Reid DT, Reyes JL, Mcdonald BA, Vo T, Reimer RA, Eksteen B (2016) Kupffer cells undergo fundamental changes during the development of experimental NASH and are critical in initiating liver damage and inflammation. PLoS ONE 11:e0159524. https://doi.org/10.1371/journal.pone.0159524
Remmerie A, Martens L, Thoné T, Castoldi A, Seurinck R, Pavie B, Roels J, Vanneste B, De Prijck S, Vanhockerhout M, Binte Abdul Latib M, Devisscher L, Hoorens A, Bonnardel J, Vandamme N, Kremer A, Borghgraef P, Van Vlierberghe H, Lippens S, Pearce E, Saeys Y, Scott CL (2020) Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver. Immunity 53:641-657e14. https://doi.org/10.1016/j.immuni.2020.08.004
Rensen SS, Bieghs V, Xanthoulea S, Arfianti E, Bakker JA, Shiri-Sverdlov R, Hofker MH, Greve JW, Buurman WA (2012) Neutrophil-derived myeloperoxidase aggravates non-alcoholic steatohepatitis in low-density lipoprotein receptor-deficient mice. PLoS ONE 7:e52411. https://doi.org/10.1371/journal.pone.0052411
Russo RC, Garcia CC, Teixeira MM, Amaral FA (2014) The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol 10:593–619. https://doi.org/10.1586/1744666x.2014.894886
Saiman Y, Friedman SL (2012) The role of chemokines in acute liver injury. Front Physiol 3:213. https://doi.org/10.3389/fphys.2012.00213
Schuster S, Cabrera D, Arrese M, Feldstein AE (2018) Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol 15:349–364. https://doi.org/10.1038/s41575-018-0009-6
Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, Bursill CA, Llovet JM, Brenner DA, Schwabe RF (2009a) CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest 119:1858–1870. https://doi.org/10.1172/jci37444
Seki E, De Minicis S, Inokuchi S, Taura K, Miyai K, Van Rooijen N, Schwabe RF, Brenner DA (2009b) CCR2 promotes hepatic fibrosis in mice. Hepatology 50:185–197. https://doi.org/10.1002/hep.22952
Semba T, Nishimura M, Nishimura S, Ohara O, Ishige T, Ohno S, Nonaka K, Sogawa K, Satoh M, Sawai S, Matsushita K, Imazeki F, Yokosuka O, Nomura F (2013) The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis. BMC Gastroenterol 13:120. https://doi.org/10.1186/1471-230x-13-120
Shan Z, Ju C (2020) Hepatic Macrophages in Liver Injury. Front Immunol 11:322. https://doi.org/10.3389/fimmu.2020.00322
Sharifnia T, Antoun J, Verriere TG, Suarez G, Wattacheril J, Wilson KT, Peek RM Jr., Abumrad NN, Flynn CR (2015) Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol 309:G270–G278. https://doi.org/10.1152/ajpgi.00304.2014
Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, Okunade AL, Patterson BW, Nyangau E, Field T, Sirlin CB, Talukdar S, Hellerstein MK, Klein S (2020) Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest 130:1453–1460. https://doi.org/10.1172/jci134165
Song J, Park KA, Lee WT, Lee JE (2014) Apoptosis signal regulating kinase 1 (ASK1): potential as a therapeutic target for Alzheimer’s disease. Int J Mol Sci 15:2119–2129. https://doi.org/10.3390/ijms15022119
Stefan N, Häring HU (2011) The metabolically benign and malignant fatty liver. Diabetes 60:2011–2017. https://doi.org/10.2337/db11-0231
Stiglund N, Strand K, Cornillet M, Stål P, Thorell A, Zimmer CL, Näslund E, Karlgren S, Nilsson H, Mellgren G, Fernø J, Hagström H, Björkström NK (2019) Retained NK cell phenotype and functionality in non-alcoholic fatty liver disease. Front Immunol 10:1255. https://doi.org/10.3389/fimmu.2019.01255
Stofan M, Guo GL (2020) Bile acids and FXR: novel targets for liver diseases. Front Med (Lausanne) 7:544. https://doi.org/10.3389/fmed.2020.00544
Sun G, Jin H, Zhang C, Meng H, Zhao X, Wei D, Ou X, Wang Q, Li S, Wang T, Sun X, Shi W, Tian D, Liu K, Xu H, Tian Y, Li X, Guo W, Jia J, Zhang Z, Zhang D (2018) OX40 regulates both innate and adaptive immunity and promotes nonalcoholic steatohepatitis. Cell Rep 25:3786-3799e4. https://doi.org/10.1016/j.celrep.2018.12.006
Sutti S, Albano E (2020) Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol 17:81–92. https://doi.org/10.1038/s41575-019-0210-2
Sutti S, Locatelli I, Bruzzì S, Jindal A, Vacchiano M, Bozzola C, Albano E (2015) CX3CR1-expressing inflammatory dendritic cells contribute to the progression of steatohepatitis. Clin Sci (Lond) 129:797–808. https://doi.org/10.1042/cs20150053
Sven MF, Pierre B, Manal FA, Quentin MA, Elisabetta B, Vlad R, Philippe HM, Bruno S, Jean-Louis J, Pierre B, Jean-Louis A (2020) A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: design of the NATIVE study. Contemp Clin Trials 98:106170. https://doi.org/10.1016/j.cct.2020.106170
Świderska M, Jaroszewicz J, Stawicka A, Parfieniuk-Kowerda A, Chabowski A, Flisiak R (2017) The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease. Clin Exp Hepatol 3(3):127–134. https://doi.org/10.5114/ceh.2017.68466
Syn WK, Oo YH, Pereira TA, Karaca GF, Jung Y, Omenetti A, Witek RP, Choi SS, Guy CD, Fearing CM, Teaberry V, Pereira FE, Adams DH, Diehl AM (2010) Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 51:1998–2007. https://doi.org/10.1002/hep.23599
Syn WK, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, Pang H, Xie G, Philips G, Chan IS, Karaca GF, Pereira Tde A, Chen Y, Mi Z, Kuo PC, Choi SS, Guy CD, Abdelmalek MF, Diehl AM (2012) NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 61:1323–1329. https://doi.org/10.1136/gutjnl-2011-301857
Szabo G (2021) Exosomes and microRNA-223 at the intersection of inflammation and fibrosis in NAFLD. Hepatology 74:5–8. https://doi.org/10.1002/hep.31805
Tang Y, Bian Z, Zhao L, Liu Y, Liang S, Wang Q, Han X, Peng Y, Chen X, Shen L, Qiu D, Li Z, Ma X (2011) Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol 166:281–290. https://doi.org/10.1111/j.1365-2249.2011.04471.x
Tomita K, Freeman BL, Bronk SF, Lebrasseur NK, White TA, Hirsova P, Ibrahim SH (2016) CXCL10-mediates macrophage, but not other innate immune cells-associated inflammation in murine nonalcoholic steatohepatitis. Sci Rep 6:28786. https://doi.org/10.1038/srep28786
Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS (2012) Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. J Biol Chem 287:40161–40172. https://doi.org/10.1074/jbc.M112.417014
Turpin-Nolan SM, Brüning JC (2020) The role of ceramides in metabolic disorders: when size and localization matters. Nat Rev Endocrinol 16:224–233. https://doi.org/10.1038/s41574-020-0320-5
Van Der Windt DJ, Sud V, Zhang H, Varley PR, Goswami J, Yazdani HO, Tohme S, Loughran P, O’doherty RM, Minervini MI, Huang H, Simmons RL, Tsung A (2018) Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatology 68:1347–1360. https://doi.org/10.1002/hep.29914
Van Herck MA, Weyler J, Kwanten WJ, Dirinck EL, De Winter BY, Francque SM, Vonghia L (2019) The differential roles of T cells in non-alcoholic fatty liver disease and obesity. Front Immunol 10:82. https://doi.org/10.3389/fimmu.2019.00082
Van Westerouen MJ, Drenth JPH, Tjwa E (2020) Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs 29:117–123. https://doi.org/10.1080/13543784.2020.1668375
Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9:503–510. https://doi.org/10.1038/ni1582
Von Vietinghoff S, Ley K (2008) Homeostatic regulation of blood neutrophil counts. J Immunol 181:5183–5188. https://doi.org/10.4049/jimmunol.181.8.5183
Wanders RJ, Waterham HR, Ferdinandusse S (2015) Metabolic interplay between peroxisomes and other subcellular organelles including mitochondria and the endoplasmic reticulum. Front Cell Dev Biol 3:83. https://doi.org/10.3389/fcell.2015.00083
Wang J (2018) Neutrophils in tissue injury and repair. Cell Tissue Res 371:531–539. https://doi.org/10.1007/s00441-017-2785-7
Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W (2008) Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 48:1632–1643. https://doi.org/10.1002/hep.22519
Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, Scholten D, Berres ML, Zimmermann H, Streetz KL, Tacke F, Hillebrandt S, Schmitz P, Keppeler H, Berg T, Dahl E, Gassler N, Friedman SL, Trautwein C (2009) Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 137:309–319. https://doi.org/10.1053/j.gastro.2009.03.053
Wen Y, Lambrecht J, Ju C, Tacke F (2021) Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol 18:45–56. https://doi.org/10.1038/s41423-020-00558-8
Westerbacka J, Kolak M, Kiviluoto T, Arkkila P, Sirén J, Hamsten A, Fisher RM, Yki-Järvinen H (2007) Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 56:2759–2765. https://doi.org/10.2337/db07-0156
Wettstein G, Luccarini JM, Poekes L, Faye P, Kupkowski F, Adarbes V, Defrêne E, Estivalet C, Gawronski X, Jantzen I, Philippot A, Tessier J, Tuyaa-Boustugue P, Oakley F, Mann DA, Leclercq I, Francque S, Konstantinova I, Broqua P, Junien JL (2017) The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis. Hepatol Commun 1:524–537. https://doi.org/10.1002/hep4.1057
Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, Stemmer K, Ringelhan M, Simonavicius N, Egger M, Wohlleber D, Lorentzen A, Einer C, Schulz S, Clavel T, Protzer U, Thiele C, Zischka H, Moch H, Tschöp M, Tumanov AV, Haller D, Unger K, Karin M, Kopf M, Knolle P, Weber A, Heikenwalder M (2014) Metabolic activation of intrahepatic CD8 + T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 26:549–564. https://doi.org/10.1016/j.ccell.2014.09.003
Wouters K, Van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lütjohann D, Kerksiek A, Van Kruchten R, Maeda N, Staels B, Van Bilsen M, Shiri-Sverdlov R, Hofker MH (2008) Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48:474–486. https://doi.org/10.1002/hep.22363
Wynn TA, Barron L (2010) Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 30:245–257. https://doi.org/10.1055/s-0030-1255354
Xiong X, Kuang H, Ansari S, Liu T, Gong J, Wang S, Zhao XY, Ji Y, Li C, Guo L, Zhou L, Chen Z, Leon-Mimila P, Chung MT, Kurabayashi K, Opp J, Campos-Pérez F, Villamil-Ramírez H, Canizales-Quinteros S, Lyons R, Lumeng CN, Zhou B, Qi L, Huertas-Vazquez A, Lusis AJ, Xu XZS, Li S, Yu Y, Li JZ, Lin JD (2019) Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol Cell 75:644-660e5. https://doi.org/10.1016/j.molcel.2019.07.028
Xu G, Wang YM, Ying MM, Chen SD, Li ZR, Ma HL, Zheng MH, Wu J, Ding C (2021a) Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis. Clin Mol Hepatol 27:329–345. https://doi.org/10.3350/cmh.2020.0261
Xu L, Chen Y, Nagashimada M, Ni Y, Zhuge F, Chen G, Li H, Pan T, Yamashita T, Mukaida N, Kaneko S, Ota T, Nagata N (2021b) CC chemokine ligand 3 deficiency ameliorates diet-induced steatohepatitis by regulating liver macrophage recruitment and M1/M2 status in mice. Metabolism 125:154914. https://doi.org/10.1016/j.metabol.2021.154914
Xu L, Liu W, Bai F, Xu Y, Liang X, Ma C, Gao L (2021c) Hepatic macrophage as a key player in fatty liver disease. Front Immunol 12:708978. https://doi.org/10.3389/fimmu.2021.708978
Yang L, Miura K, Zhang B, Matsushita H, Yang YM, Liang S, Song J, Roh YS, Seki E (2017) TRIF differentially regulates hepatic steatosis and inflammation/fibrosis in mice. Cell Mol Gastroenterol Hepatol 3:469–483. https://doi.org/10.1016/j.jcmgh.2016.12.004
Ye D, Yang K, Zang S, Lin Z, Chau HT, Wang Y, Zhang J, Shi J, Xu A, Lin S, Wang Y (2016) Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2. J Hepatol 65:988–997. https://doi.org/10.1016/j.jhep.2016.05.041
Yilmaz H, Yalcin KS, Namuslu M, Celik HT, Sozen M, Inan O, Nadir I, Turkay C, Akcay A, Kosar A (2015) Neutrophil-lymphocyte ratio (NLR) could be better predictor than C-reactive protein (CRP) for liver fibrosis in non-alcoholic steatohepatitis (NASH). Ann Clin Lab Sci 45:278–286
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15:11–20. https://doi.org/10.1038/nrgastro.2017.109
Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, Macconell L, Shringarpure R, Harrison S, Sanyal AJ (2019) Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394:2184–2196. https://doi.org/10.1016/s0140-6736(19)33041-7
Zhang S, Wang J, Liu Q, Harnish DC (2009) Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 51:380–388. https://doi.org/10.1016/j.jhep.2009.03.025
Zhang X, Shen J, Man K, Chu ES, Yau TO, Sung JC, Go MY, Deng J, Lu L, Wong VW, Sung JJ, Farrell G, Yu J (2014) CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. J Hepatol 61:1365–1375. https://doi.org/10.1016/j.jhep.2014.07.006
Zhao X, Yang L, Chang N, Hou L, Zhou X, Yang L, Li L (2020) Neutrophils undergo switch of apoptosis to NETosis during murine fatty liver injury via S1P receptor 2 signaling. Cell Death Dis 11:379. https://doi.org/10.1038/s41419-020-2582-1
Acknowledgements
This work was supported by the National Research Foundation of Korea (NRF) Grant funded by the Korea Government (MSIT) (Grant Nos. 2021R1F1A1056033 and 2022R1C1C1003563) (S.H.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Chung, K.W., Cho, Y.E., Kim, SJ. et al. Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis. Arch. Pharm. Res. 45, 229–244 (2022). https://doi.org/10.1007/s12272-022-01379-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-022-01379-1